Cure Alzheimer's Fund

Supports Alzheimer's disease research initiatives and care innovation to speed new treatment options and patient outcomes.

Cure Alzheimer's Fund is a US 501(c)(3) public charity and DBA of the Alzheimer's Disease Research Foundation, headquartered in Wellesley, Massachusetts. Founded in 2004, it funds research aimed exclusively at understanding and curing Alzheimer's disease, while supporting scientists at universities, medical centers, and research institutions worldwide.

Its grantmaking runs through a single rolling letter-of-inquiry path rather than fixed annual deadlines. Proposals are reviewed by a Research Leadership Group and a Board Research Committee, and the organization reports about 6,400 projects funded since inception, including 120 new projects in 2024. Research is organized around seven active consortia covering Tau, APOE, the blood-brain barrier, microbiome, neuroimmune biology, brain aging, and sleep and circadian rhythms.

The funder's position is unusually focused for a philanthropy of its size: it backs one disease area, works with institutions worldwide, and uses collaborative consortia to push shared biological questions rather than a broad open-call model. That makes it a strong fit for Alzheimer's teams that can justify a direct line from mechanism to cure-oriented work, including projects that need a clear path from discovery biology into translational follow-on studies.